Drug Profile


Alternative Names: ALLOD-2H; ALLOD2; ATNC 05

Latest Information Update: 27 Jun 2017

Price : $50

At a glance

  • Originator Allodynic Therapeutics
  • Class Analgesics; Antimigraines
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Migraine
  • Phase II Back pain

Most Recent Events

  • 30 Jun 2017 Allodynic Therapeutics plans the ANODYNE-4 phase II/III trial for Back pain (NCT03201393)
  • 27 Jun 2017 Allodynic Therapeutics plans the ANODYNE-3 phase II/III trial for Migraine (Prevention), in June 2017 (NCT03194555)
  • 27 Jun 2017 Allodynic Therapeutics initiates enrolment in the phase II/III ANODYNE-2 trial for Migraine in USA (NCT03185143)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top